Table 3 Prescription DAM combinations and additional long-acting slow-release opioid agonists (n = 52)
n (%) | Baseline | 4-week follow-up |
|---|---|---|
PO and IN | – | 23 (44.2) |
IN only | – | 13 (25.0) |
IV and PO and IN | – | 7 (13.5) |
IV and IN | – | 3 (5.8) |
PO only | 22 (42.3) | 2 (3.8) |
IV and PO | 8 (15.4) | 2 (3.8) |
IM and IN | – | 1 (1.9) |
IM and PO | 5 (9.6) | 1 (1.9) |
IV only | 8 (15.4) | 0 (0.0) |
IM only | 3 (5.8) | 0 (0.0) |
No DAM | 6 (11.5) | 0 (0.0) |
Any injected DAM | 24 (46.2) | 14 (27.0) |
Any IN DAM | 0 (0.0) | 47 (90.4) |
Additional methadone or levomethadone | 12 (23.1) | 11 (21.2) |
Additional SROM | 27 (51.9) | 29 (55.8) |